Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1999, for Bio-Rad Laboratories, Inc., a Delaware corporation headquartered in Hercules, California. The company operates in three primary segments: Life Science, Clinical Diagnostics, and Analytical Instruments. As of April 30, 1999, the company had 9,974,862 shares of Class A Common Stock and 2,487,716 shares of Class B Common Stock outstanding.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 |
|---|---|---|
| Net Sales | $125,738,000 | $116,174,000 |
| Gross Profit | $70,182,000 | $64,076,000 |
| Gross Margin | 55.8% | 55.2% |
| Income from Operations | $16,631,000 | $13,107,000 |
| Net Income | $10,802,000 | $8,776,000 |
| Diluted EPS | $0.89 | $0.71 |
| Cash and Equivalents | $8,036,000 | $12,626,000 (End of Q1 1998) |
| Operating Cash Flow | $1,405,000 | $(88,000) |
| Total Debt (Current + Long-term) | $51,134,000 | $51,732,000 (Dec 31, 1998) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8.2% year-over-year to a record $125.7 million. Clinical Diagnostics grew 12% and Life Science grew 10%, while Analytical Instruments declined 5% due to a slowdown in the semiconductor market.
- Margin Expansion: Consolidated gross margin improved to 55.8% from 55.2%. This was driven by favorable currency effects in Europe and manufacturing variances in Clinical Diagnostics, offsetting increased manufacturing costs in Life Science.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased as a percentage of sales (34.2% vs. 35.4%), while R&D expenses increased 6% year-over-year.
- Cash Flow: Operating cash flow turned positive at $1.4 million compared to a slight usage of $88,000 in the prior year. However, cash and cash equivalents decreased by $2.0 million during the quarter due to investing and financing activities.
Outlook, Risks, and Management Commentary
- Capital Expenditures: CapEx is expected to increase substantially in 1999. A potential relocation of the Life Science facility in Northern California could require a $25 million commitment over two years, pending a final decision.
- Stock Repurchases: The Board has authorized up to $18 million in stock repurchases. The company has repurchased $14.1 million worth of stock since July 1996.
- Year 2000 (Y2K) Risk: The company estimates $8 million in total remediation costs, with approximately 75% already incurred. Management notes that while internal systems are being addressed, the readiness of significant suppliers and global infrastructure remains a material uncertainty that could disrupt operations.
- Euro Transition: The company is adjusting internal systems for the Euro introduction but does not expect a material impact on financial position, though competitive pressures may increase.
- Acquisitions: The company continues to review acquisition opportunities, including those that could materially impact liquidity.
Investor Verification Checklist
- Verify the status of the potential $25 million facility relocation project and its impact on future capital allocation.
- Monitor the progress of supplier Y2K readiness assessments, as the company has not yet received sufficient responses to rule out material disruption.
- Track the performance of the Analytical Instruments segment, which is currently facing headwinds from the semiconductor industry slowdown.
- Review the sustainability of the effective tax rate (29%), which currently benefits from loss carryforwards and foreign tax credits that may not continue indefinitely.
- Confirm the timeline for the completion of the Euro transition and its effect on European sales pricing and margins.